These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 21626545)

  • 1. Milestones in movement disorders clinical trials: advances and landmark studies.
    Olanow CW; Wunderle KB; Kieburtz K
    Mov Disord; 2011 May; 26(6):1003-14. PubMed ID: 21626545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
    Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
    Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A "cure" for Parkinson's disease: can neuroprotection be proven with current trial designs?
    Clarke CE
    Mov Disord; 2004 May; 19(5):491-8. PubMed ID: 15133811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
    Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
    Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings.
    Marras C; Lang AE
    Expert Rev Neurother; 2004 Nov; 4(6):985-93. PubMed ID: 15853525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease.
    Friedman JH; Alves G; Hagell P; Marinus J; Marsh L; Martinez-Martin P; Goetz CG; Poewe W; Rascol O; Sampaio C; Stebbins G; Schrag A
    Mov Disord; 2010 May; 25(7):805-22. PubMed ID: 20461797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A responsive outcome for Parkinson's disease neuroprotection futility studies.
    Elm JJ; Goetz CG; Ravina B; Shannon K; Wooten GF; Tanner CM; Palesch YY; Huang P; Guimaraes P; Kamp C; Tilley BC; Kieburtz K;
    Ann Neurol; 2005 Feb; 57(2):197-203. PubMed ID: 15668964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New anxiolytic drugs: methodological issues].
    Ginestet D; Corruble E
    Encephale; 1993; 19(6):627-37. PubMed ID: 12404782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trials of neuroprotective therapies for Parkinson's disease: problems and limitations.
    de la Fuente-Fernández R; Schulzer M; Mak E; Sossi V
    Parkinsonism Relat Disord; 2010 Jul; 16(6):365-9. PubMed ID: 20471298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blinding protocols, treatment credibility, and expectancy: methodologic issues in clinical trials of osteopathic manipulative treatment.
    Licciardone JC; Russo DP
    J Am Osteopath Assoc; 2006 Aug; 106(8):457-63. PubMed ID: 16943515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychogenic movement disorders: past developments, current status, and future directions.
    Lang AE; Voon V
    Mov Disord; 2011 May; 26(6):1175-86. PubMed ID: 21626561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis.
    Ploeger BA; Holford NH
    Pharm Stat; 2009; 8(3):225-38. PubMed ID: 19025967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
    Clarke CE
    Mov Disord; 2008 Apr; 23(6):784-9. PubMed ID: 18175348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.